Elevated circulating miR-182 acts as a diagnostic biomarker for early colorectal cancer
Authors Liu X, Xu T, Hu X, Chen X, Zeng K, Sun L, Wang S
Received 24 November 2017
Accepted for publication 14 February 2018
Published 24 April 2018 Volume 2018:10 Pages 857—865
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Professor Nakshatri
Xiangxiang Liu, Tao Xu, Xiuxiu Hu, XiaoXiang Chen, Kaixuan Zeng, Li Sun, Shukui Wang
Central Laboratory, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of China
Purpose: Globally, colorectal cancer (CRC) is one of the most common cancers with high mortality. Although CRC patients in stages I–II are curable after surgical resection, due to the lack of sensitive and specific biomarkers, many patients are in the advanced stages when diagnosed. This study aimed to investigate whether circulating miRNAs in plasma could act as biomarkers for early CRC diagnosis.
Patients and methods: All healthy subjects and patients were from Nanjing First Hospital. We first selected 2 differential miRNAs by integrated analysis of 4 Gene Expression Omnibus (GEO) data sets and The Cancer Genome Atlas (TCGA) database. Next, the expression of these 2 miRNAs in tissue and plasma samples were examined through quantitative real-time polymerase chain reaction. Training phase and validation phase were designed to investigate the diagnostic utility of these differential miRNAs using receiver operating characteristic (ROC) curve analysis.
Results: After integrated analysis of 4 GEO and TCGA databases, upregulated miR-182 and miR-20a were selected to further investigate their diagnostic potential for CRC. We discovered that miR-182 and miR-20a were upregulated in CRC tissue and plasma and that circulating miR-182 and miR-20a in the plasma of CRC patients were tumor derived. The area under the ROC curve (AUC) of circulating miR-182 was 0.929 (95% CI 0.875–0.983) in the training phase and 0.891 (95% CI 0.821–0.961) in the validation phase. The AUC of circulating miR-20a expression was 0.801 (95% CI 0.695–0.906) in the training phase and 0.736 (95% CI 0.631–0.842) in the validation phase.
Conclusion: Circulating miR-182 is a novel potential biomarker for early CRC diagnosis.
Keywords: miRNAs, colorectal cancer, GEO database, TCGA database, biomarker
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]